Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | MAOB | P27338 | 8/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6655573 | 0.81 | KMT2A (0.60) | KDM4EPOLBHRH3MAOBMAOA | |
| SCHEMBL6649042 | 0.81 | HRH3 (0.52) | HRH3MAOBMAOADRD2 | |
| SCHEMBL25059606 | 0.80 | KDM4E (0.67) | KDM4EHRH3MAOB | |
| SCHEMBL6651979 | 0.80 | MEN1 (0.52) | HRH3MAOBMAOA | |
| SCHEMBL9057922 | 0.78 | LMNA (0.70) | SMN1; SMN2HRH3DRD2 | |
| SCHEMBL3886790 | 0.78 | KDM4E (0.59) | KDM4ESMN1; SMN2HRH3DRD2 | |
| SCHEMBL10207398 | 0.77 | ALDH1A1 (0.68) | KDM4ESMN1; SMN2HRH3 | |
| Hydrochloric Acid SCHEMBL6725886 | 0.76 | HRH3 (0.51) | KDM4EPOLBSMN1; SMN2HRH3DRD2 | |
| SCHEMBL13091445 | 0.76 | KDM4E (0.71) | KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL10696776 | 0.75 | HRH3 (0.56) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143971-B1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PF MEDICAMENT (FR) | 2004-06-02 | — | — | EP | disclosed |
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | PIERRE FABRE MEDICAMENT (FR) | 2004-01-22 | — | — | US | disclosed |
| US-6583159-B1 | Myocardial ischemia; cytoprotective properties | PIERRE FABRE MEDICAMENT (FR) | 2003-06-24 | — | — | US | disclosed |
| EP-1143971-A1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PIERRE FABRE MEDICAMENT (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000043011-A1 | SUBSTITUTED 1-(PIPERIDIN-4-YL)-3-(ARYL)-ISOTHIOUREAS, THEIR PREPARATION AND THERAPEUTIC USE | PIERRE FABRE MEDICAMENT (FR) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014785-A1 | Substituted 1-(piperidin-4-YL)-3-(aryl)-isothioureas, their preparation and therapeutic use | AQP1, SLCO2A1, SLCO2B1 | KDM4E 2806/4885POLB 1008/4885SMN1; SMN2 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.